HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	toripalimab Sensitive: C2 – Inclusion Criteria ESMO-IO 2023 - 2 days (New C3) toripalimab Sensitive : C2 ESMO-IO 2023 - 2d	toripalimab Sensitive: C2 – Inclusion Criteria ESMO-IO 2023 - 2 days toripalimab Sensitive : C2 ESMO-IO 2023 - 2 days - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib + eFT226 Sensitive: B - Late Trials BioSpace - 4 days (New B) abemaciclib + eFT226 Sensitive : B BioSpace - 4d	abemaciclib + eFT226 Sensitive: B - Late Trials BioSpace - 4 days abemaciclib + eFT226 Sensitive : B BioSpace - 4 days - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ESMO Asia 2023 - 5 days (New C3) ribociclib Sensitive : A1 ESMO Asia 2023 - 5d	ribociclib Sensitive: A1 - Approval ESMO Asia 2023 - 5 days ribociclib Sensitive : A1 ESMO Asia 2023 - 5 days - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria ESMO Asia 2023 - 5 days (New C3) H3B-6545 Sensitive : C2 ESMO Asia 2023 - 5d	H3B-6545 Sensitive: C2 – Inclusion Criteria ESMO Asia 2023 - 5 days H3B-6545 Sensitive : C2 ESMO Asia 2023 - 5 days - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	carboplatin + eribulin mesylate Sensitive: C3 – Early Trials ESMO Asia 2023 - 5 days (New C3) carboplatin + eribulin mesylate Sensitive : C3 ESMO Asia 2023 - 5d	carboplatin + eribulin mesylate Sensitive: C3 – Early Trials ESMO Asia 2023 - 5 days carboplatin + eribulin mesylate Sensitive : C3 ESMO Asia 2023 - 5 days - (New C3)
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks (New A1) capivasertib Sensitive : A1 AstraZeneca Press Release - 2wk	capivasertib Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks capivasertib Sensitive : A1 AstraZeneca Press Release - 2 weeks - (New A1)
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks (New A1) capivasertib Sensitive : A1 AstraZeneca Press Release - 2wk	capivasertib Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks capivasertib Sensitive : A1 AstraZeneca Press Release - 2 weeks - (New A1)
PTEN mutation + HR positive	HER2 Negative Breast Cancer	PTEN mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks (New A1) capivasertib Sensitive : A1 AstraZeneca Press Release - 2wk	capivasertib Sensitive: A1 - Approval AstraZeneca Press Release - 2 weeks capivasertib Sensitive : A1 AstraZeneca Press Release - 2 weeks - (New A1)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	HER2 inhibitor Sensitive: C3 – Early Trials Hum Pathol - 2 weeks (New C3) HER2 inhibitor Sensitive : C3 Hum Pathol - 2wk	HER2 inhibitor Sensitive: C3 – Early Trials Hum Pathol - 2 weeks HER2 inhibitor Sensitive : C3 Hum Pathol - 2 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole + SAR439859 Sensitive: C3 – Early Trials Breast Cancer Res - 3 weeks (New C3) letrozole + SAR439859 Sensitive : C3 Breast Cancer Res - 3wk	letrozole + SAR439859 Sensitive: C3 – Early Trials Breast Cancer Res - 3 weeks letrozole + SAR439859 Sensitive : C3 Breast Cancer Res - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1	alpelisib Sensitive: A1 - Approval alpelisib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1	elacestrant Sensitive: A1 - Approval elacestrant Sensitive : A1
BRCA2 deletion	HER2 Negative Breast Cancer	BRCA2 deletion	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 deletion	HER2 Negative Breast Cancer	BRCA1 deletion	HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	HR negative + BRCA1 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2	eribulin mesylate Sensitive: A2 - Guideline eribulin mesylate Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
BRCA2 mutation	HER2 Negative Breast Cancer	BRCA2 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
BRCA1 mutation	HER2 Negative Breast Cancer	BRCA1 mutation	HER2 Negative Breast Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2	ixabepilone Sensitive: A2 - Guideline ixabepilone Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2	toremifene Sensitive: A2 - Guideline toremifene Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2	letrozole Sensitive: A2 - Guideline letrozole Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2	anastrozole Sensitive: A2 - Guideline anastrozole Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2	docetaxel + capecitabine Sensitive: A2 - Guideline docetaxel + capecitabine Sensitive : A2

HER2 Negative Breast Cancer

Associations(508)

Associations
(508)